Recital 22, Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 20…

In forcesince 16 Apr 2014

In practice, in order to reach recruitment targets or for other reasons, sponsors may have an interest in extending the clinical trial to an additional Member States after the initial authorisation of the clinical trial. An authorisation mechanism should be provided to allow for such extension, while avoiding the re-assessment of the application by all the Member States concerned which were involved in the initial authorisation of the clinical trial.